Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction on October 7, 2013, where Mrs. K Thomson (Connected Person to Director Mr. P C Thomson) acquired 29,330 Ordinary Shares. The purchase price was 1,566.36 pence per share. This acquisition resulted from the re-investment of the dividend paid to shareholders on October 3, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(c) regarding the notification of the connected person's transaction.
Investor Verification Points
- Verify the share price of 1,566.36 pence per share on October 7, 2013.
- Confirm the dividend payment date of October 3, 2013, and the reinvestment mechanism.
- Check the total shareholding of Mrs. K Thomson post-transaction to assess concentration.
- Review the relationship between Mr. P C Thomson and Mrs. K Thomson as defined in the company's connected person register.